Scientists at Sanofi created digital counterparts of people with Pompe disease to support drug development and advance Pompe disease treatment. In a simulated clinical trial of digital twins with infantile-onset Pompe disease (IOPD), Sanofi’s Nexviazyme (avalglucosidase alfa), an enzyme replacement therapy, outperformed its first-generation Lumizyme (alglucosidase alfa)…
AI
Recent Posts
- No Pompe journeys are the same, but we don’t have to walk this road alone
- Patient interviews reveal experiences with Pompe treatment and trials
- My daughter with Pompe disease is brave, but every kid has their limits
- Study maps molecular changes in Pompe muscle cells
- Parenting a child with Pompe comes with worries about an uncertain future